Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer
cells and either kill them or deliver cancer-killing substances to them without harming
normal cells. Combining combination chemotherapy with monoclonal antibody therapy may kill
more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus rituximab
in treating patients who have relapsed non-Hodgkin's lymphoma.